SCI Engineered Materials, Inc.: Form 10-Q for the period ended Sep 30, 2021
Filed with the SEC on Oct 27, 2021 and accepted by EDGAR at Oct 27, 2021, 08:01 ET.
Management's discussion and analysis
As filed, 4,931 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Two additional issues are affecting national and global market conditions. First, supply chain disruptions have become more frequent in recent months for the Company and some of its customers. Thus far, we have not experienced material adverse effects regarding product shipments; however, timely sourcing of certain materials is of increased concern. Second, published articles and corporate announcements continue to address the global semiconductor chip shortage, which is anticipated to continue into 2022. It is affecting some of our customers which could impact the Company’s revenue, volume, and profitability. We continue to actively monitor these developments, including ongoing contact with our suppliers and customers, and adapting to their specific circumstances and forecasts.
On April 17, 2020, we entered into an unsecured promissory note under the Paycheck Protection Program (the “PPP”), with a principal amount of $325,300. The PPP was established under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) and administered by the U.S. Small Business Administration (the “SBA”). The SBA approved our Forgiveness Application in full on January 6, 2021.
The Employee Retention Credit, as originally enacted on March 27, 2020, by the CARES Act, is a refundable tax credit against certain employment taxes equal to 50% of the qualified wages an eligible employer pays to employees after March 12, 2020, and before January 1, 2021. The Taxpayer Certainty and Disaster Tax Relief Act (the “Relief Act”), enacted on December 27, 2020, amended, and extended the ERC. On March 1, 2021, the IRS released Notice 2021-20 to provide guidance on the original ERC, as modified by the Relief Act. During 2021 we filed Form 941-X to claim a credit of $105,000 on qualified wages paid in 2020. This receivable appears on the balance sheet as of September 30, 2021, as Tax Receivable, and as a credit to wages in the Statement of Operations during the nine months ended September 30, 2021.
The Relief Act extended and enhanced the Employee Retention Credit for qualified wages paid after December 31, 2020, through June 30, 2021. Under the Relief Act, eligible employers may claim a refundable tax credit against certain employment taxes equal to 70% of the qualified wages an eligible employer pays to employees after December 31, 2020, through June 30, 2021. As of the March 11, 2021 passage of the American Rescue Plan Act, the ERC is available for all four quarters of 2021.
During the first quarter of 2021, we experienced a decline in gross receipts of 25% compared to the first quarter of 2019. This decline, along with continued underutilization of certain manufacturing equipment, reduction in employee’s workloads, travel restrictions and supply chain issues, qualified us to receive this credit. We filed Form 941 for the first quarter of 2021 and claimed a credit of $150,507 on qualified wages paid in the first quarter of 2021. These funds were received during the second quarter of 2021 and appear as a credit to wages in the Statement of Operations during the nine months ended September 30, 2021. An employer that has a decline continues to be eligible until the end of the calendar quarter in which gross receipts are greater than 80% of its 2019 calendar quarter receipts. Thus, we were eligible for this credit for the second quarter of 2021 in the amount of $151,701, which appears as a credit to wages in the Statement of Operations for the nine months ended September 30, 2021.
During the second quarter of 2021, we experienced a decline in gross receipts of 30% compared to the second quarter of 2019. This decline, along with continued underutilization of certain manufacturing equipment, reduction in employee’s workloads, travel restrictions and supply chain issues, qualified us to receive this credit for the third quarter of 2021. As previously mentioned, an employer that has a decline in gross receipts continues to be eligible until the end of the calendar quarter in which gross receipts are greater than 80% of its 2019 calendar quarter receipts. Thus, we were eligible for this credit for the third quarter of 2021 in the amount of $153,713, which appears as a credit to wages in the Statement of Operations for the three and nine months ended September 30, 2021. $73,852 was applied as a credit to payroll taxes throughout the third quarter and the remainder appears on the balance sheet as Tax Receivable as of September 30, 2021.
In addition, the American Rescue Plan Act of 2021 allows eligible employers with fewer than 500 employees to qualify for a tax credit for providing paid time off for each employee receiving COVID-19 vaccinations and for any time needed to recover from the vaccine. The Company received a credit of $11,042 and this amount appears as a credit to wages in the Statement of Operations for the three and nine months ended September 30, 2021.
Controls and procedures
As filed, 2,808 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and implemented, can only provide reasonable assurance of achieving the desired control objectives. Management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including the Chief Executive Officer and Chief Financial Officer, to allow timely discussions regarding required disclosure.
Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective. Disclosure controls and procedures are defined by Rules 13a-15(e) and 15d-15(e) of the Exchange Act as controls and other procedures that are designed to ensure that information required to be disclosed by us in reports filed with the SEC under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms.
Inherent Limitations over Internal Controls
Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations of management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of assets that could have a material effect on the financial statements.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2021-07-01 to 2021-09-30 | $5.2m | us-gaap:Revenues |
| Revenue | 9 months2021-01-01 to 2021-09-30 | $10.2m | us-gaap:Revenues |
| Cost of revenue | 3 months2021-07-01 to 2021-09-30 | $3.9m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2021-01-01 to 2021-09-30 | $7.5m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2021-07-01 to 2021-09-30 | $1.3m | us-gaap:GrossProfit |
| Gross profit | 9 months2021-01-01 to 2021-09-30 | $2.7m | us-gaap:GrossProfit |
| Research and development | 3 months2021-07-01 to 2021-09-30 | $56.6k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2021-01-01 to 2021-09-30 | $149.2k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2021-07-01 to 2021-09-30 | $877.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2021-01-01 to 2021-09-30 | $1.5m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2021-07-01 to 2021-09-30 | $200.2k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2021-01-01 to 2021-09-30 | $338.3k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2021-07-01 to 2021-09-30 | $668.7k | us-gaap:NetIncomeLoss |
| Net income | 9 months2021-01-01 to 2021-09-30 | $1.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2021-07-01 to 2021-09-30 | $0.15 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2021-01-01 to 2021-09-30 | $0.32 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2021-07-01 to 2021-09-30 | $0.15 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2021-01-01 to 2021-09-30 | $0.32 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2021-07-01 to 2021-09-30 | 4,531,523 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2021-01-01 to 2021-09-30 | 4,521,746 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2021-01-01 to 2021-09-30 | $1.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2021-01-01 to 2021-09-30 | $615.1k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2021-09-30 | $4.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-09-30 | $6.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-09-30 | $10.1m | us-gaap:Assets |
| Current liabilities | At period end2021-09-30 | $2.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-09-30 | $3.0m | us-gaap:Liabilities |
| Shareholders' equity | At period end2021-09-30 | $7.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001104659-21-130289. Last ingested by Listed: Oct 29, 2026, 08:02 ET. Listed shows no prices and gives no investment advice.